



## Clinical trial results: Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intramuscular Route)

### Summary

EudraCT number	2009-017690-38
Trial protocol	FR
Global end of trial date	27 May 2010

### Results information

Result version number	v1 (current)
This version publication date	16 February 2016
First version publication date	03 December 2014

### Trial information

#### Trial identification

Sponsor protocol code	GRT90
-----------------------	-------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01121822
WHO universal trial number (UTN)	U1111-1112-8285

Notes:

### Sponsors

Sponsor organisation name	Sanofi Pasteur SA
Sponsor organisation address	1541, Avenue Marcel Mérieux, Marcy L'Etoile, France, 69280
Public contact	Director, Clinical Development, Sanofi Pasteur SA, 33 (0)4 37 37 53 50, diane.vandervliet@sanofipasteur.com
Scientific contact	Director, Clinical Development, Sanofi Pasteur SA, 33 (0)4 37 37 53 50, diane.vandervliet@sanofipasteur.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	21 June 2010
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	27 May 2010
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

1) To evaluate the compliance, in terms of immunogenicity, of the influenza vaccine (split virion, inactivated) Northern Hemisphere (NH) 2010-2011 formulation with the requirements of the Committee for Proprietary Medicinal Products (CPMP) Note for Guidance (NfG) CPMP/BWP/214/96 in both age groups

2) To describe the safety of the influenza vaccine (split virion, inactivated) NH 2010-2011 formulation in both age groups

Protection of trial subjects:

Only subjects who met all the study inclusion and none of the exclusion criteria were vaccinated in the study. Vaccinations were performed by qualified and trained study personnel. Subjects with allergy to any of the vaccine components were not vaccinated. After vaccination, subjects were also kept under clinical observation for 30 minutes to ensure their safety. Appropriate medical equipment were also available on site in case of any immediate allergic reactions.

Background therapy:

Not applicable

Evidence for comparator:

Not applicable

Actual start date of recruitment	05 May 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	France: 129
Worldwide total number of subjects	129
EEA total number of subjects	129

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	99
From 65 to 84 years	30
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Study subjects were enrolled from 05 May 2010 to 27 May 2010 in 3 clinical centers in France.

### Pre-assignment

Screening details:

A total of 129 subjects who met all inclusion criteria and none of the exclusion criteria were enrolled and vaccinated.

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

Not applicable

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	18 to 60 years

Arm description:

Subjects aged 18 to 60 years who received one dose of inactivated, split-virion influenza vaccine, Northern Hemisphere 2010-2011 formulation on day 0.

Arm type	Experimental
Investigational medicinal product name	Influenza vaccine (split virion, inactivated)
Investigational medicinal product code	314
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

0.5 mL, intramuscular into the deltoid muscle, one dose at Day 0.

<b>Arm title</b>	61 years or older
------------------	-------------------

Arm description:

Subjects aged 61 years or older who received one dose of inactivated, split-virion influenza vaccine, Northern Hemisphere 2010-2011 formulation on day 0.

Arm type	Experimental
Investigational medicinal product name	Influenza vaccine (split virion, inactivated)
Investigational medicinal product code	314
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

0.5 mL, intramuscular into the deltoid muscle, one dose at Day 0.

<b>Number of subjects in period 1</b>	18 to 60 years	61 years or older
Started	64	65
Completed	63	64
Not completed	1	1
Adverse event, non-fatal	-	1
Protocol deviation	1	-

## Baseline characteristics

### Reporting groups

Reporting group title	18 to 60 years
Reporting group description: Subjects aged 18 to 60 years who received one dose of inactivated, split-virion influenza vaccine, Northern Hemisphere 2010-2011 formulation on day 0.	
Reporting group title	61 years or older
Reporting group description: Subjects aged 61 years or older who received one dose of inactivated, split-virion influenza vaccine, Northern Hemisphere 2010-2011 formulation on day 0.	

Reporting group values	18 to 60 years	61 years or older	Total
Number of subjects	64	65	129
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	64	35	99
From 65-84 years	0	30	30
85 years and over	0	0	0
Age continuous			
Units: years			
arithmetic mean	37.6	66.7	
standard deviation	± 14.3	± 5.3	-
Gender categorical			
Units: Subjects			
Female	30	38	68
Male	34	27	61
Previous seasonal influenza vaccination			
Units: Subjects			
Yes	11	27	38
No	53	38	91

## End points

### End points reporting groups

Reporting group title	18 to 60 years
Reporting group description:	
Subjects aged 18 to 60 years who received one dose of inactivated, split-virion influenza vaccine, Northern Hemisphere 2010-2011 formulation on day 0.	
Reporting group title	61 years or older
Reporting group description:	
Subjects aged 61 years or older who received one dose of inactivated, split-virion influenza vaccine, Northern Hemisphere 2010-2011 formulation on day 0.	

### Primary: Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies Before and After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2010-2011 Formulation by the Intramuscular Route

End point title	Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies Before and After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2010-2011 Formulation by the Intramuscular Route <sup>[1]</sup>
End point description:	
Influenza vaccine antibodies were assessed using the hemagglutination inhibition technique.	
End point type	Primary
End point timeframe:	
Day 0 (pre-vaccination) and Day 21 post vaccination	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 60 years	61 years or older		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	64	64		
Units: Titers				
geometric mean (confidence interval 95%)				
A/California/7/2009 (H1N1) like Strain (Day 0)	14.3 (9.57 to 21.4)	8.64 (6.92 to 10.8)		
A/Perth/16/2009(H3N2) like Strain (Day 0)	16.9 (11.8 to 24.3)	14.8 (10.7 to 20.3)		
Whole B/Brisbane/60/2008 like Strain (Day 0)	11.6 (9.09 to 14.9)	10.3 (7.9 to 13.4)		
Split B/Brisbane/60/2008 like Strain (Day 0)	27.5 (19.6 to 38.7)	26.2 (18.3 to 37.6)		
A/California/7/2009 (H1N1) like Strain (Day 21)	385 (261 to 568)	199 (125 to 315)		
A/Perth/16/2009(H3N2) like Strain (Day 21)	504 (367 to 693)	368 (246 to 552)		
Whole B/Brisbane/60/2008 like Strain (Day 21)	157 (120 to 206)	51.9 (37.6 to 71.6)		
Split B/Brisbane/60/2008 like Strain (Day 21)	626 (477 to 822)	225 (167 to 304)		

## Statistical analyses

No statistical analyses for this end point

### Primary: Geometric Mean Titers Ratios (GMTR) of Influenza Vaccine Antibodies After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2010-2011 Formulation by the Intramuscular Route

End point title	Geometric Mean Titers Ratios (GMTR) of Influenza Vaccine Antibodies After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2010-2011 Formulation by the Intramuscular Route <sup>[2]</sup>
-----------------	---

#### End point description:

Influenza vaccine antibodies were assessed using the hemagglutination inhibition technique. Geometric mean titer ratio is the geometric mean of the individual post-vaccination/pre-vaccination titer of antibodies to the influenza virus antigens.

End point type	Primary
----------------	---------

#### End point timeframe:

Day 0 (pre-vaccination) and Day 21 post vaccination

#### Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 60 years	61 years or older		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	64	64		
Units: Titer Ratios				
geometric mean (confidence interval 95%)				
A/California/7/2009 (H1N1) like Strain	26.9 (17.5 to 41.4)	23 (14.9 to 35.4)		
A/Perth/16/2009(H3N2) like Strain	29.8 (20.5 to 43.3)	24.9 (16.7 to 37.4)		
Whole B/Brisbane/60/2008 like Strain	13.5 (9.4 to 19.5)	5.05 (3.47 to 7.34)		
Split B/Brisbane/60/2008 like Strain	22.8 (15.3 to 33.8)	8.58 (5.59 to 13.2)		

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects Achieving a Titer of < 10 (1/dil) Against the Influenza Vaccine Antigens Before and After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2010-2011 Formulation by the Intramuscular Route



End point title	Percentage of Subjects Achieving a Titer of < 10 (1/dil) Against the Influenza Vaccine Antigens Before and After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2010-2011 Formulation by the Intramuscular Route <sup>[3]</sup>
End point description: Influenza vaccine antibodies were assessed using the hemagglutination inhibition technique.	
End point type	Primary
End point timeframe: Day 0 (pre-vaccination) and Day 21 post vaccination	

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 60 years	61 years or older		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	64	64		
Units: Percentage of subjects				
number (not applicable)				
A/California/7/2009 (H1N1) like Strain (Day 0)	60.9	65.6		
A/Perth/16/2009(H3N2) like Strain (Day 0)	39.1	42.2		
Whole B/Brisbane/60/2008 like Strain (Day 0)	48.4	59.4		
Split B/Brisbane/60/2008 like Strain (Day 0)	28.1	29.7		
A/California/7/2009 (H1N1) like Strain (Day 21)	0	3.1		
A/Perth/16/2009(H3N2) like Strain (Day 21)	0	1.6		
Whole B/Brisbane/60/2008 like Strain (Day 21)	0	6.3		
Split B/Brisbane/60/2008 like Strain (Day 21)	0	0		

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects with Seroprotection Against the Influenza Vaccine Antigens Before and After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2010-2011 Formulation by the Intramuscular Route

End point title	Percentage of Subjects with Seroprotection Against the Influenza Vaccine Antigens Before and After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2010-2011 Formulation by the Intramuscular Route <sup>[4]</sup>
End point description: Influenza vaccine antibodies were assessed using the hemagglutination inhibition technique. Seroprotection was defined as titers $\geq 40$ (1/dil) on Day 0 and Day 21.	
End point type	Primary

End point timeframe:

Day 0 (pre-vaccination) and Day 21 post vaccination

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 60 years	61 years or older		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	64	64		
Units: Percentage of subjects				
number (not applicable)				
A/California/7/2009 (H1N1) like Strain (Day 0)	26.6	9.4		
A/Perth/16/2009(H3N2) like Strain (Day 0)	21.09	20.3		
Whole B/Brisbane/60/2008 like Strain (Day 0)	20.3	15.6		
Split B/Brisbane/60/2008 like Strain (Day 0)	51.6	45.3		
A/California/7/2009 (H1N1) like Strain (Day 21)	92.2	81.3		
A/Perth/16/2009(H3N2) like Strain (Day 21)	100	93.8		
Whole B/Brisbane/60/2008 like Strain (Day 21)	95.3	64.1		
Split B/Brisbane/60/2008 like Strain (Day 21)	100	93.8		

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects with Seroconversion or Significant Increase Against the Influenza Vaccine Antigens Before and After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2010-2011 Formulation by Intramuscular Route

End point title	Percentage of Subjects with Seroconversion or Significant Increase Against the Influenza Vaccine Antigens Before and After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2010-2011 Formulation by Intramuscular Route <sup>[5]</sup>
-----------------	--

End point description:

Influenza vaccine antibodies were assessed using the hemagglutination inhibition technique. Seroconversion was defined as subjects with a titer <10 (1/dil) on Day 0 and a post-injection titer ≥40 (1/dil) on Day 21 or significant increase was defined as subjects with a titer ≥10 (1/dil) on Day 0 and a ≥4-fold increase from pre- to post-injection titer on Day 21.

End point type	Primary
----------------	---------

End point timeframe:

Day 21 post-vaccination

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine

administered for this outcome.

End point values	18 to 60 years	61 years or older		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	64	64		
Units: Percentage of subjects				
number (not applicable)				
A/California/7/2009 (H1N1) like Strain	78.1	79.7		
A/Perth/16/2009(H3N2) like Strain	89.1	84.4		
Whole B/Brisbane/60/2008 like Strain	78.1	45.3		
Split B/Brisbane/60/2008 like Strain	87.5	59.4		

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects with at Least One Reaction Corresponding to those Listed in the EMEA Note for Guidance Within 3 Days After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2010-2011 Formulation (Intramuscular Route)

End point title	Percentage of Subjects with at Least One Reaction Corresponding to those Listed in the EMEA Note for Guidance Within 3 Days After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2010-2011 Formulation (Intramuscular Route) <sup>[6]</sup>
-----------------	--

End point description:

Solicited injection site: Induration and Ecchymosis. Solicited systemic reactions: Pyrexia, Malaise, and Shivering.

End point type	Primary
----------------	---------

End point timeframe:

Day 0 up to Day 3 post-vaccination

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 60 years	61 years or older		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	64	65		
Units: Percentage of subjects				
number (not applicable)				
Injection site induration ≥5 cm for 4 days	0	0		
Injection site ecchymosis	6.3	0		
Pyrexia (>38°C for at least 1 day)	3.1	1.5		
Malaise	7.8	6.2		
Shivering	9.4	1.5		

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects Reporting Solicited Injection-site or Systemic Reactions within 3 Days After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2010-2011 Formulation by the Intramuscular Route

End point title	Percentage of Subjects Reporting Solicited Injection-site or Systemic Reactions within 3 Days After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2010-2011 Formulation by the Intramuscular Route <sup>[7]</sup>
-----------------	---

End point description:

Solicited injection site: Pain, Erythema, Swelling, Induration and Ecchymosis. Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Shivering. Grade 3 injection site: Pain – Significant, prevents daily activity; Erythema, Swelling, Induration, and Ecchymosis – >10 cm. Grade 3 systemic reactions: Fever – ≥39.0°C; Headache, Malaise, Myalgia, and Shivering – Significant, prevents daily activity.

End point type	Primary
----------------	---------

End point timeframe:

Day 0 up to Day 3 post-vaccination

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 60 years	61 years or older		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	64	65		
Units: Percentage of subjects				
number (not applicable)				
Injection site Pain	53.1	20		
Grade 3 Injection site Pain	0	0		
Injection site Erythema	1.6	1.5		
Grade 3 Injection site Erythema	0	0		
Injection site Swelling	1.6	1.5		
Grade 3 Injection site Swelling	0	0		
Injection site Induration	4.7	0		
Grade 3 Injection site Induration	0	0		
Injection site Ecchymosis	0	0		
Grade 3 Injection site Ecchymosis	0	0		
Fever	3.1	1.5		
Grade 3 Fever	0	0		
Headache	23.4	9.2		
Grade 3 Headache	1.6	0		
Malaise	7.8	6.2		
Grade 3 Malaise	0	0		

Myalgia	25	10.8		
Grade 3 Myalgia	0	0		
Shivering	9.4	1.5		
Grade 3 Shivering	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects Reporting Solicited Injection-site or Systemic Reactions More than 3 Days After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2010-2011 Formulation by the Intramuscular Route

End point title	Percentage of Subjects Reporting Solicited Injection-site or Systemic Reactions More than 3 Days After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2010-2011 Formulation by the Intramuscular Route <sup>[8]</sup>
-----------------	--

End point description:

Solicited injection site: Pain, Erythema, Swelling, Induration and Ecchymosis. Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Shivering. Grade 3 injection site: Pain – Significant, prevents daily activity; Erythema, Swelling, Induration, and Ecchymosis – >10 cm. Grade 3 systemic reactions: Fever – ≥39.0°C; Headache, Malaise, Myalgia, and Shivering – Significant, prevents daily activity.

End point type	Primary
----------------	---------

End point timeframe:

>Day 3 post-vaccination

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 60 years	61 years or older		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	64	65		
Units: Percentage of subjects				
number (not applicable)				
Injection site Pain	0	0		
Grade 3 Injection site Pain	0	0		
Injection site Erythema	0	0		
Grade 3 Injection site Erythema	0	0		
Injection site Swelling	0	0		
Grade 3 Injection site Swelling	0	0		
Injection site Induration	0	0		
Grade 3 Injection site Induration	0	0		
Injection site Ecchymosis	0	0		
Grade 3 Injection site Ecchymosis	0	0		
Fever	0	1.5		
Grade 3 Fever	0	0		
Headache	9.4	1.5		
Grade 3 Headache	0	0		

Malaise	3.1	1.5		
Grade 3 Malaise	0	0		
Myalgia	3.1	1.5		
Grade 3 Myalgia	0	0		
Shivering	1.6	0		
Grade 3 Shivering	0	0		

## Statistical analyses

No statistical analyses for this end point

### **Primary: Percentage of Subjects Reporting a Solicited Injection-site or Systemic Reactions Within 7 Days After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2010-2011 Formulation by the Intramuscular Route**

End point title	Percentage of Subjects Reporting a Solicited Injection-site or Systemic Reactions Within 7 Days After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2010-2011 Formulation by the Intramuscular Route <sup>[9]</sup>
-----------------	---

End point description:

Solicited injection site: Pain, Erythema, Swelling, Induration and Ecchymosis. Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Shivering.

End point type	Primary
----------------	---------

End point timeframe:

Day 0 up to Day 7 post-vaccination

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

<b>End point values</b>	18 to 60 years	61 years or older		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	64	65		
Units: Percentage of subjects				
number (not applicable)				
Injection site Pain	53.1	20		
Injection site Erythema	1.6	1.5		
Injection site Swelling	1.6	1.5		
Injection site Induration	4.7	0		
Injection site Ecchymosis	0	0		
Fever	3.1	3.1		
Headache	32.8	10.8		
Malaise	10.9	7.7		
Myalgia	28.1	12.3		
Shivering	10.9	1.5		

## Statistical analyses



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse event data were collected from Day 0 (post-vaccination) up to Day 21 post-vaccination.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	12.0
--------------------	------

### Reporting groups

Reporting group title	18 to 60 years
-----------------------	----------------

Reporting group description:

Subjects aged 18 to 60 years who received one dose of inactivated, split-virion influenza vaccine, Northern Hemisphere 2010-2011 formulation on day 0.

Reporting group title	61 years or older
-----------------------	-------------------

Reporting group description:

Subjects aged 61 years or older who received one dose of inactivated, split-virion influenza vaccine, Northern Hemisphere 2010-2011 formulation on day 0.

Serious adverse events	18 to 60 years	61 years or older	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 64 (0.00%)	1 / 65 (1.54%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Renal and urinary disorders			
Left ureter lithiasis			
subjects affected / exposed	0 / 64 (0.00%)	1 / 65 (1.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	18 to 60 years	61 years or older	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	34 / 64 (53.13%)	13 / 65 (20.00%)	
Nervous system disorders			
Headache			
alternative assessment type: Systematic			
subjects affected / exposed	21 / 64 (32.81%)	7 / 65 (10.77%)	
occurrences (all)	21	7	



General disorders and administration site conditions			
Injection site ecchymosis			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 64 (6.25%)	0 / 65 (0.00%)	
occurrences (all)	4	0	
Malaise			
alternative assessment type: Systematic			
subjects affected / exposed	7 / 64 (10.94%)	5 / 65 (7.69%)	
occurrences (all)	7	5	
Shivering			
alternative assessment type: Systematic			
subjects affected / exposed	7 / 64 (10.94%)	1 / 65 (1.54%)	
occurrences (all)	7	1	
Injection site pain			
alternative assessment type: Systematic			
subjects affected / exposed	34 / 64 (53.13%)	13 / 65 (20.00%)	
occurrences (all)	34	13	
Musculoskeletal and connective tissue disorders			
Myalgia			
alternative assessment type: Systematic			
subjects affected / exposed	18 / 64 (28.13%)	8 / 65 (12.31%)	
occurrences (all)	18	8	
Infections and infestations			
Pharyngitis			
subjects affected / exposed	5 / 64 (7.81%)	0 / 65 (0.00%)	
occurrences (all)	5	0	

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported